Literature DB >> 33033047

Use of Cangrelor in Cervical and Intracranial Stenting for the Treatment of Acute Ischemic Stroke: A "Real Life" Single-Center Experience.

A Cervo1, F Ferrari1,2, G Barchetti3, L Quilici1, M Piano1, E Boccardi1, G Pero4.   

Abstract

BACKGROUND AND
PURPOSE: In cases of large-vessel-occlusion strokes due to an underlying tandem internal carotid artery occlusion or intracranial atherosclerotic disease, concomitant stent placement may be needed. Immediate platelet inhibition is necessary, but to date, a standardized approach for antiplatelet inhibition in acute settings is still missing. Here we report our single-center experience about the safety and efficacy of periprocedural administration of cangrelor in patients with acute ischemic stroke due to intracranial or cervical artery occlusion undergoing stent placement.
MATERIALS AND METHODS: We retrospectively evaluated all cases of acute ischemic stroke that needed acute stent implantation and were treated with periprocedural administration of cangrelor between January 2019 and April 2020 at our institution. All patients who needed either extracranial or intracranial artery stent placement (in either the anterior or posterior circulation) were included.
RESULTS: We evaluated 38 patients in whom cangrelor was administered IV periprocedurally. Their mean age was 64 years (range, 26-85 years), with 25/38 male subjects and 13/38 female patients. In 26 patients (68.4%), a tandem occlusion was present and was treated with carotid artery stent placement, while 12 patients (31.6%) required an intracranial stent implantation. In 4 subjects (10.5%), an intracerebral hemorrhage occurred after the procedure. All patients in the series were alive 1 week after the procedure.
CONCLUSIONS: Although larger, multicentric randomized studies are strongly warranted, our results support the hypothesis of a possible role of cangrelor as a valuable therapeutic option in the management of platelet inhibition in acute ischemic stroke procedures after intra- or extracranial stent placement.
© 2020 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33033047      PMCID: PMC7658814          DOI: 10.3174/ajnr.A6785

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  24 in total

1.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).

Authors:  Marco Valgimigli; Héctor Bueno; Robert A Byrne; Jean-Philippe Collet; Francesco Costa; Anders Jeppsson; Peter Jüni; Adnan Kastrati; Philippe Kolh; Laura Mauri; Gilles Montalescot; Franz-Josef Neumann; Mate Petricevic; Marco Roffi; Philippe Gabriel Steg; Stephan Windecker; Jose Luis Zamorano; Glenn N Levine
Journal:  Eur Heart J       Date:  2018-01-14       Impact factor: 29.983

2.  The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity.

Authors:  R F Storey; H M Sanderson; A E White; J A May; K E Cameron; S Heptinstall
Journal:  Br J Haematol       Date:  2000-09       Impact factor: 6.998

3.  Emergent carotid stenting and intra-arterial abciximab in acute ischemic stroke due to tandem occlusion.

Authors:  Fawaz Al-Mufti; Krishna Amuluru; Nathan W Manning; Imad Khan; Lissa Peeling; Chirag D Gandhi; Charles J Prestigiacomo; Galyna Pushchinska; David Fiorella; Henry H Woo
Journal:  Br J Neurosurg       Date:  2017-03-15       Impact factor: 1.596

4.  Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety.

Authors:  Joseph S Van Tuyl; Andrea Sikora Newsome; Ian B Hollis
Journal:  Ann Pharmacother       Date:  2019-01-16       Impact factor: 3.154

5.  The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.

Authors:  N L Dovlatova; J A Jakubowski; A Sugidachi; S Heptinstall
Journal:  J Thromb Haemost       Date:  2008-07-01       Impact factor: 5.824

Review 6.  Endovascular Treatment of Acute Ischemic Stroke Due to Tandem Occlusions: Large Multicenter Series and Systematic Review.

Authors:  Mikayel Grigoryan; Diogo C Haussen; Ameer E Hassan; Andrey Lima; Jonathan Grossberg; Leticia C Rebello; Wondwossen Tekle; Michael Frankel; Raul G Nogueira
Journal:  Cerebrovasc Dis       Date:  2016-02-17       Impact factor: 2.762

7.  Intravenous cangrelor and oral ticagrelor as an alternative to clopidogrel in acute intervention.

Authors:  Italo Linfante; Kaushik Ravipati; Amy Kathryn Starosciak; Dennys Reyes; Guilherme Dabus
Journal:  J Neurointerv Surg       Date:  2020-05-15       Impact factor: 5.836

Review 8.  Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment.

Authors:  Christine A Holmstedt; Tanya N Turan; Marc I Chimowitz
Journal:  Lancet Neurol       Date:  2013-11       Impact factor: 44.182

Review 9.  Neuro-Interventional Use of Oral Antiplatelets: A Survey of Neuro-Endovascular Centers in the United States and Review of the Literature.

Authors:  Salia Farrokh; Kent Owusu; Lucia Rivera Lara; Katharine Nault; Ferdinand Hui; Brian Spoelhof
Journal:  J Pharm Pract       Date:  2019-07-21

Review 10.  Pathophysiology and management of reperfusion injury and hyperperfusion syndrome after carotid endarterectomy and carotid artery stenting.

Authors:  Muhammad U Farooq; Christopher Goshgarian; Jiangyong Min; Philip B Gorelick
Journal:  Exp Transl Stroke Med       Date:  2016-09-06
View more
  6 in total

1.  Safety and Efficacy of Cangrelor in Acute Stroke Treated with Mechanical Thrombectomy: Endovascular Treatment of Ischemic Stroke Registry and Meta-analysis.

Authors:  G Marnat; S Finistis; F Delvoye; I Sibon; J-P Desilles; M Mazighi; F Gariel; A Consoli; C Rosso; F Clarençon; M Elhorany; C Denier; V Chalumeau; J Caroff; L Veunac; F Bourdain; J Darcourt; J-M Olivot; R Bourcier; C Dargazanli; C Arquizan; S Richard; B Lapergue; B Gory
Journal:  AJNR Am J Neuroradiol       Date:  2022-03-03       Impact factor: 3.825

2.  Use of intravenous cangrelor and stenting in acute ischemic stroke interventions: a new single center analysis and pooled-analysis of current studies.

Authors:  Alexandra R Paul; Pouya Entezami; Devin Holden; Nicholas Field; John Dalfino; Alan Boulos
Journal:  Interv Neuroradiol       Date:  2021-05-04       Impact factor: 1.610

Review 3.  Endovascular Treatment of Large Vessel Occlusion Strokes Due to Intracranial Atherosclerotic Disease.

Authors:  Jin Soo Lee; Seong-Joon Lee; Ji Man Hong; Francisco José Arruda Mont Alverne; Fabricio Oliveira Lima; Raul G Nogueira
Journal:  J Stroke       Date:  2022-01-31       Impact factor: 6.967

4.  Safety of Low Dose Intravenous Cangrelor in Acute Ischemic Stroke: A Case Series.

Authors:  Hisham Salahuddin; Giana Dawod; Syed F Zaidi; Julie Shawver; Richard Burgess; Mouhammad A Jumaa
Journal:  Front Neurol       Date:  2021-06-04       Impact factor: 4.003

5.  A Multicenter Preliminary Study of Cangrelor following Thrombectomy Failure for Refractory Proximal Intracranial Occlusions.

Authors:  G Marnat; F Delvoye; S Finitsis; B Lapergue; F Gariel; A Consoli; J-P Desilles; M Mazighi; C Dargazanli; R Bourcier; J Darcourt; V Chalumeau; M Elhorany; F Clarençon; S Richard; B Gory; I Sibon
Journal:  AJNR Am J Neuroradiol       Date:  2021-06-11       Impact factor: 4.966

Review 6.  P2Y12 inhibitors for the neurointerventionalist.

Authors:  Robin J Borchert; Davide Simonato; Charlotte R Hickman; Maurizio Fuschi; Lucie Thibault; Hans Henkes; David Fiorella; Benjamin Yq Tan; Leonard Ll Yeo; Hegoda L D Makalanda; Ken Wong; Pervinder Bhogal
Journal:  Interv Neuroradiol       Date:  2021-05-04       Impact factor: 1.610

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.